Targeting of immune cells slows cancer growth in pre-clinical studies
Researchers have discovered a new cancer immunotherapy approach that shrinks solid tumours.
List view / Grid view
Researchers have discovered a new cancer immunotherapy approach that shrinks solid tumours.
Dr Larysa Baraban, physicist at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) is researching a chip that should ultimately make it possible to develop personalised cancer immunotherapies.
Researchers have eradicated malignant tumours in mice by combining an immunotherapy agent with a molecular delivery system that targets tumour acidity.
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
Discover why the Hyperion+ Imaging System is the standard to assess tumour-immune interactions and get deep single-cell insights.
A report has shown that the immuno-oncology drug discovery outsourcing market is set to be worth $2563 million by 2030.
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
A new high-throughput approach has shown how patients whose tumours express CD58 are more likely to respond to CAR T-cell therapy.
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
The approach mimics the physical forces exerted by T cells as they crawl over host cells, could help scientists develop more effective cancer immunotherapies.
A new study has shown that lactate, a metabolic byproduct produced during exercise, could augment current cancer immunotherapies.
Researchers have revealed the immune landscape and microbiome of pancreatic cysts as they progress to pancreatic cancer, providing targets for immunotherapy.
New study finds that using CRISPR to block RASA2 gene makes T cells more resilient against cancer.